Erlotinib Tarceva 埃罗替尼
Tarceva News Center 特罗凯新闻中心
Tarceva Erlotinib 它塞瓦 ; 它赛瓦
Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy.
特罗凯在美国和欧盟被批准用于非小细胞肺癌化疗后一线治疗。
In pancreatic cancer trials, the incidence of these events was 2.5% in the Tarceva group and 0.4% in the placebo group.
胰腺癌试验中,特罗凯组中发生这些事件的比率为2.5%,安慰剂组中此比率为0.4%。
The drug Tarceva, which costs about $3, 500 a month, was approved as a treatment for pancreatic cancer because it improved survival by 12 days.
比如使用特赛瓦抗癌药(Tarceva),一个月的花费大概是3500美元,但就因为它被证实可以延长患者12天的生命而被批准为胰腺癌的治疗用药。
应用推荐